68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue 11, 2016, Pages 1720-1725

  Fendler, Wolfgang P ^a   Schmidt, Dorothea F ^a   Wenter, Vera ^a   Thierfelder, Kolja M ^b   Zach, Christian ^a   Stief, Christian ^a,b   Bartenstein, Peter ^a   Kirchner, Thomas ^a   Gildehaus, Franz J ^a   Gratzke, Christian ^a,b   Faber, Claudius ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Biopsy; PET; Prostate cancer; PSMA

Indexed keywords

GALLIUM 68 PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ADULT; AGED; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; IMAGE ENHANCEMENT; MIDDLE AGED; PATHOLOGY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; REPRODUCIBILITY; TUMOR INVASION;

ADULT; AGED; ALGORITHMS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84994797910     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.172627     Document Type: Article

References (19)

1. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: A systematic review and meta-Analysis. AJR. 2012;199:103- 110.
2. Sonn GA, Chang E, Natarajan S, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014;65:809-815.
3. Muller BG, Shih JH, Sankineni S, et al. Prostate cancer: interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multiparametric MR imaging. Radiology. 2015;277:741-750.
4. Mowatt G, Scotland G, Boachie C, et al. The diagnostic accuracy and costeffectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: A systematic review and economic evaluation. Health Technol Assess. 2013;17:vii-xix, 1-281.
5. Hartenbach M, Hartenbach S, Bechtloff W, et al. Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: A prospective diagnostic trial. Clin Cancer Res. 2014;20:3244-3253.
6. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41: 11-20.
7. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197- 209.
8. Weineisen M, Schottelius M, Simecek J, et al. 68Ga-And 177Lu-labeled PSMA I&T: optimization of a PSMA-Targeted theranostic concept and first proof-ofconcept human studies. J Nucl Med. 2015;56:1169-1176.
9. NEMA NU 2: Performance Measurements of Positron Emission Tomographs. Rosslyn, VA: National Electrical Manufacturers Association; 2001:11-12.
10. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
11. Billis A, Freitas LL, Magna LA, Samara AB, Ferreira U. Prostate cancer with bladder neck involvement: pathologic findings with application of a new practical method for tumor extent evaluation and recurrence-free survival after radical prostatectomy. Int Urol Nephrol. 2004;36:363-368.
12. Huber F, Montani M, Sulser T, et al. Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer: What has gone wrong? A blueprint for the way forward in biomarker studies. Br J Cancer. 2015;112:140-148.
13. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
14. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003-1010.
15. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-172.
16. Ben Jemaa A, Bouraoui Y, Sallami S, et al. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res. 2010;29:171.
17. Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M. 68Ga- PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2015;40:1769-1771.
18. Zettinig O, Shah A, Hennersperger C, et al. Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. Int J Comput Assist Radiol Surg. 2015;10:1997-2007.
19. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer. 1998;82:2256-2261.